{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.5","upperLimit":"64.1","value":"50.8"},{"groupId":"OG001","lowerLimit":"33.6","upperLimit":"56.6","value":"44.9"},{"groupId":"OG002","lowerLimit":"33.0","upperLimit":"60.3","value":"46.4"},{"groupId":"OG003","lowerLimit":"48.8","upperLimit":"73.9","value":"61.9"},{"groupId":"OG004","lowerLimit":"39.5","upperLimit":"55.2","value":"47.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"167"}],"units":"Participants"}],"description":"ORR was defined as percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). For participants with metastatic disease, Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm) \\<1 (centimeter (cm). -PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab 3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks (Q2W) during each 8-week treatment cycle, for up to 96 weeks (12 cycles).","id":"OG000","title":"Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W"},{"description":"Participants received cemiplimab 3 mg/kg IV Q2W during each 8-week treatment cycle, for up to 96 weeks (12 cycles).","id":"OG001","title":"Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W"},{"description":"Participants received cemiplimab 350 mg IV every 3 weeks (Q3W) during each 9-week treatment cycle, for up to 54 weeks (6 cycles).","id":"OG002","title":"Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W"},{"description":"Participants received cemiplimab 600 mg IV every 4 weeks (Q4W) during each 8-week treatment cycle, for up to 48 weeks (6 cycles).","id":"OG003","title":"Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W"},{"description":"Participants received cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 108 weeks (12 cycles).","id":"OG004","title":"Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) included all enrolled participants. Only Groups 1, 2, 3, 4, and 6 were planned for this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 108 weeks","title":"Overall Response Rate (ORR) by Independent Central Review","type":"PRIMARY","unitOfMeasure":"percentage of participants"}